SAVANNAH — Hyundai has begun producing electric SUVs in Georgia less than two years after breaking ground on its $7.6 billion ...

The Supreme Court on Monday rejected an appeal from Martin Shkreli, who was once dubbed “Pharma Bro” after jacking up the ...

The U.S. Supreme Court on Monday rejected appeals from two high-profile figures: R&B singer R. Kelly, and former ...

The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 ...

Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...

Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...

The judge cited Shkreli’s “particularly heartless and coercive” tactics in monopolizing Daraprim and keeping generic rivals ...

The Swiss pharma giant is trying to establish a presence in the increasingly crowded obesity field and expand in therapeutic areas such as ophthalmology, in an attempt to turn a page on past ...

Estimates range from $2.8 billion per approval by Tufts (2016) industry-wide to staggering $6.1 billion per approval within Big Pharma according to the recent St. Gallen consortium paper.

And the person replied, “Oh, they know you. I’ve heard back door conversations of people who work at pharma companies talk about ‘that #insulin4all girl’.” Since then, we at ...

Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price target remains the same with $275.00. Michael Ulz has ...